Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-labeled, Randomized, Single Dose, Three Period, 2-sequence Crossover Study to Investigate the Pharmacokinetics of Darifenacin When Given as 7.5 mg Oral Doses of a Modified Release Suspension, as Compared to the Commercial Modified Release Tablet in Healthy Adult

NCT00413426 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00413426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00413426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-labeled, Randomized, Single Dose, Three Period, 2-sequence Crossover Study to Investigate the Pharmacokinetics of Darifenacin When Given as 7.5 mg Oral Doses of a Modified Release Suspension, as Compared to the Commercial Modified Release Tablet in Healthy Adult
Lead sponsor
Novartis
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2006
Completion date
September 30, 2007
Enrollment
28
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy